HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis

BACKGROUND: Trastuzumab-based therapy is a standard, targeted treatment for HER2-positive breast cancer in the adjuvant setting. However, patients do not benefit equally from it and the association between HER2 amplification level and patients' survival remains controversial. A systematic revie...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qian-Qian, Pan, Bo, Wang, Chang-Jun, Zhou, Yi-Dong, Mao, Feng, Lin, Yan, Guan, Jing-Hong, Shen, Song-Jie, Zhang, Xiao-Hui, Xu, Ya-Li, Zhong, Ying, Wang, Xue-Jing, Zhang, Yan-Na, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325386/
https://www.ncbi.nlm.nih.gov/pubmed/27566580
http://dx.doi.org/10.18632/oncotarget.11541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5325386/
https://www.ncbi.nlm.nih.gov/pubmed/27566580
http://dx.doi.org/10.18632/oncotarget.11541

Ejemplares similares